Portal de investigación
EUTOXRISK21. AN INTEGRATED EUROPEAN ‘FLAGSHIP’ PROGRAM DRIVING MECHANISM-BASED.
Datos básicos
- Protocolo:
- 681002_EUTOXRISK_CASTELL_H2020-PHC-33-2015
- EUDRACT:
- NCT:
- Centro:
- Año de incio:
- 2016
- Año de finalización:
- 2021
Documentos
- No hay documentos
Participantes
-
Bernardo Roque Bort Martí
Colaborador/A
-
José Vicente Castell Ripoll
Investigador Principal
-
Laia Tolosa Pardo
Colaborador/A
-
María José Gómez-Lechón Moliner
Colaborador/A
-
Mireia López Riera
Licenciado
-
Maria Ballester Carrio
Investigador
-
María Pelechá Salvador
Licenciado
-
Arturo López Castel
Licenciado
-
Erika Moro Castaño
Técnico Apoyo Investigación
-
Mónica Aceves Tejero
Doctor
-
Marta Moreno Torres
Licenciado
Grupos
-
Hepatología experimental y Trasplante hepático
Investigador Principal
Laia Tolosa Pardo
-
Unidad Mixta de Investigación en Hepatología Experimental
Investigador Principal
Ramiro Jover Atienza
Financiadores - Promotores
Resultados del Ensayo Clínico
CELL SOURCES FOR HEPATIC CELL THERAPY
EUGENIA PAREJA IBARS, MARÍA JOSÉ GÓMEZ-LECHÓN MOLINER, LAIA TOLOSA PARDO
Capítulo de un Libro. 2017
CELL-BASED THERAPEUTIC STRATEGIES FOR TREATMENT OF LIVER DISEASES.
LAIA TOLOSA PARDO, MARÍA JOSÉ GÓMEZ-LECHÓN MOLINER, EUGENIA PAREJA IBARS
Capítulo de un Libro. 2017
Embryonic Development of the Liver
Zaret, Kenneth S., Bort, Roque, Duncan, Stephen A.
Capítulo de un Libro. 2020
In vitro personalised model based on induced pluripotent stem cells for studying idiosyncratic hepatotoxicity
Pelecha, M.; (...); Tolosa, L.
Meeting Abstract. 10.1016/j.toxlet.2024.07.291. 2024
3D HYDROGEL MICROENVIROMENTS OF GELATIN AND HYALURONIC ACID FOR LIVER TISSUE ENGINEERING
Gallego-Ferrer, Gloria; (...); Tolosa, Laia
Article. 2022
A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury
García-Cañaveras JC; (...); Lahoz A
Article. 10.1038/srep27239. 2016
A microRNA signature for valproate-induced steatosis in human hepatocytes and its application to predict fatty liver in paediatric epileptic patients on valproate therapy.
Soluyanova P; (...); Jover R
Article. 10.1016/j.tox.2024.153974. 2024
A Multi-Parametric Fluorescent Assay for the Screening and Mechanistic Study of Drug-Induced Steatosis in Liver Cells in Culture.
Tolosa, Laia, Gomez-Lechon, M Jose, Donato, M Teresa
Article. 10.1002/cptx.20. 2017
A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.
Article. 10.1002/mnfr.201900487. 2019
A novel microRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug-induced liver injury patients.
López-Riera M; (...); Jover R
Article. 10.1093/toxsci/kfz138. 2020
A Novel UPLC-MS Metabolomic Analysis-Based Strategy to Monitor the Course and Extent of iPSC Differentiation to Hepatocytes.
Moreno-Torres, Marta; (...); Castell, V, Jose
Article. 10.1021/acs.jproteome.1c00779. 2022
A read-across case study on chronic toxicity of branched carboxylic acids (1): Integration of mechanistic evidence from new approach methodologies (NAMs) to explore a common mode of action.
Escher, Sylvia E.; (...); Fisher, Ciaran
Art Exhibit Review. 10.1016/j.tiv.2021.105269. 2022
A robust reprogramming strategy for generating hepatocyte-like cells usable in pharmaco-toxicological studies.
Garcia-Llorens, Guillem; (...); Bort, Roque
Article. 10.1186/s13287-023-03311-w. 2023
Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems
Fernandez-Murga, ML; (...); Jover, R
Review. 10.1016/j.fct.2018.07.017. 2018
Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis
Article. 10.1016/j.taap.2016.04.007. 2016
Alternative Cell Sources to Adult Hepatocytes for Hepatic Cell Therapy.
Pareja, E, Gomez-Lechon, MJ, Tolosa, L
Article. 10.1007/978-1-4939-6506-9_2. 2017
Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis
Garcia-Monzon, C; (...); Jover, R
Article. 10.1016/j.ajpath.2018.07.028. 2018
Angiopoietin-like protein 8 is a novel vitamin D receptor-targeted lipogenic gene associated with non-alcoholic fatty liver
Gonzalez-Rodriguez, A; (...); Garcia-Monzon, C
Meeting Abstract. 10.1016/S0168-8278(18)30948-6. 2018
Application of high-content screening for the study of hepatotoxicity: Focus on food toxicology.
Review. 10.1016/j.fct.2020.111872. 2021
Assessment of the cytotoxic potential of an aqueous-ethanolic extract from Thalassia testudinum angiosperm marine grown in the Caribbean Sea.
Rodeiro, I; (...); Lopes, M
Article. 10.1111/jphp.13001. 2018
Automated generation of hiPSC-derived hepatic progeny by cost-efficient compounds.
Vanmarcke G; (...); Verfaillie CM
Article. 10.1093/stmcls/sxad065. 2023
Bladder cancer recurrence surveillance by urine metabolomics analysis
Loras, A; (...); Ruiz-Cerda, JL
Article. 10.1038/s41598-018-27538-3. 2018
Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to develop new predictive biomarkers for early drug development
Article. 10.1016/j.toxlet.2016.10.008. 2016
Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models.
Article. 10.3390/antiox11010086. 2021
Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases?
Tolosa L, Pareja E, Gomez-Lechon MJ
Review. 10.1097/TP.0000000000001426. 2016
Cluster-Partial Least Squares (c-PLS) regression analysis: Application to miRNA and metabolomic data.
Kuligowski, Julia; (...); Quintas, Guillermo
Article. 10.1016/j.aca.2023.342052. 2024
Co-culture of multiple myeloma cell lines and bone marrow mesenchymal stem cells in a 3D microgel environment.
Garcia-Briega, M Inmaculada; (...); Ribelles, Jose Luis Gomez
Article. 10.1016/j.bioadv.2025.214243. 2025
Comparing in vitro human liver models to in vivo human liver using RNA-Seq.
Gupta R; (...); Caiment F
Article. 10.1007/s00204-020-02937-6. 2020
Comparing Targeted vs. Untargeted MS2 Data-Dependent Acquisition for Peak Annotation in LC-MS Metabolomics
Ten-Domenech, I; (...); Kuligowski, J
Article. 10.3390/metabo10040126. 2020
Comparing the direct assessment of steatosis in liver explants with mid- and near-infrared vibrational spectroscopy, prior to organ transplantation.
Rienda, Ivan; (...); Quintas, Guillermo
Article. 10.1039/d3an01184d. 2023
Computational Strategies for Assessing Adverse Outcome Pathways: Hepatic Steatosis as a Case Study.
Ortega-Vallbona R; (...); Serrano-Candelas E
Article. 10.3390/ijms252011154. 2024
Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury
Tolosa, L; (...); Teresa Donato, M.
Article. 10.1007/s00204-017-2036-4. 2018
Challenges and perspectives of liver tissue engineering: From cell therapy to bioprinting
Rodriguez-Fernandez, Julio; (...); Tolosa, Laia
Review. 10.36922/ijb.2706. 2024
Characterization of Proliferating Human Hepatocytes As a Model System for Drug Interaction Studies and Toxicity Screenings
Noerenberg, A; (...); Jover, R
Meeting Abstract. 2017
Derivation of healthy hepatocyte-like cells from a female patient with ornithine transcarbamylase deficiency through X-inactivation selection.
Santamaria R; (...); Bort R
Article. 10.1038/s41598-022-06184-w. 2022
Direct conversion of human fibroblast to hepatocytes using a single inducible polycistronic vector.
Ballester M; (...); Bort R
Article. 10.1186/s13287-019-1416-5. 2019
Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
Lopez-Pascual, Ernesto; (...); Castell, Jose V.
Article. 10.3390/ijms25105203. 2024
Dysfunctional mitochondrial fission impairs cell reprogramming.
Prieto J; (...); Torres J
Article. 10.1080/15384101.2016.1241930. 2016
Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming
Prieto J; (...); Torres J
Article. 10.1038/ncomms11124. 2016
Enhancing the accuracy of mid-infrared spectroscopy-based liver steatosis quantification using digital image analysis as a reference.
Rienda, Ivan; (...); Quintas, Guillermo
Article. 10.1039/d3an00324h. 2023
Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes.
Article. 10.1007/s00204-019-02643-y. 2020
Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis.
Moreno-Torres M; (...); Castell JV
Article. 10.3390/ijms25053003. 2024
Extending metabolome coverage for untargeted metabolite profiling of adherent cultured hepatic cells
García-Cañaveras JC; (...); Lahoz A
Article. 10.1007/s00216-015-9227-8. 2016
Extracting consistent biological information from functional results of metabolomic pathway analysis using the Mantel's test.
Ten-Doménech I; (...); Kuligowski J
Article. 10.1016/j.aca.2021.339173. 2021
Factors that influence the quality of metabolomics data in in vitro cell toxicity studies: a systematic survey.
Moreno-Torres, Marta; (...); Castell, Jose Vicente
Article. 10.1038/s41598-021-01652-1. 2021
Glutamine/glutamate metabolism rewiring in reprogrammed human hepatocyte-like cells
Ballester, M; (...); Bort, R
Article. 10.1038/s41598-019-54357-x. 2019
Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients.
Perez-Rubio, Alvaro; (...); Jover, Ramiro
Article. 10.3390/nu15143187. 2023
Hepatocyte transplantation program: Lessons learned and future strategies
Review. 10.3748/wjg.v22.i2.874. 2016
High-Content Screening for the Detection of Drug-Induced Oxidative Stress in Liver Cells.
Review. 10.3390/antiox10010106. 2021
Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening
Review. 10.1007/s00204-016-1756-1. 2016
Human hepatocytes encapsulated in injectable hydrogels for their use in liver cell therapy
Rodriguez-Fernandez, J.; (...); Tolosa, L.
Meeting Abstract. 2019
Human Upcyte Hepatocytes: Characterization of the Hepatic Phenotype and Evaluation for Acute and Long-Term Hepatotoxicity Routine Testing
Article. 10.1093/toxsci/kfw078. 2016
Improved in vivo efficacy of clinical-grade cryopreserved human hepatocytes in mice with acute liver failure
Bolonio, M.; (...); Tolosa, L.
Meeting Abstract. 2019
Improved in vivo efficacy of clinical-grade cryopreserved human hepatocytes in mice with acute liver failure.
Article. 10.1016/j.jcyt.2019.12.005. 2020
In vitro modulation of the cytochrome P450 and ABCB1/P-glycoprotein activities of the aqueous extract of Allophylus cominia (L) Sw. leaves.
Pérez CL; (...); Rodeiro I
Article. 10.1515/dmpt-2017-0020. 2017
In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assay
Brecklinghaus, Tim; (...); Hengstler, Jan G.
Article. 10.1016/j.toxlet.2022.08.006. 2022
Induced pluripotent stem cells for the treatment of liver diseases: challenges and perspectives from a clinical viewpoint
Pareja, E, Gomez-Lechon, MJ, Tolosa, L
Review. 10.21037/atm.2020.02.164. 2020
Injectable cell-laden gelatin-chondroitin sulphate hydrogels for liver in vitro models.
Sanchez-Gonzalez, E; (...); Gallego-Ferrer, G
Article. 10.1016/j.ijbiomac.2024.138693. 2024
Long-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytes.
Tolosa, L; (...); Donato, MT
Article. 10.1007/s00204-018-2349-y. 2019
Low density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial Hypercholesterolemia modelling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection
Caron, J; (...); Dubart-Kupperschmitt, A
Meeting Abstract. 10.1016/S0168-8278(18)30382-9. 2018
Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Caron J; (...); Dubart-Kupperschmitt A
Article. 10.1186/s13287-019-1342-6. 2019
Magnetically Activated Piezoelectric 3D Platform Based on Poly(Vinylidene) Fluoride Microspheres for Osteogenic Differentiation of Mesenchymal Stem Cells
Guillot-Ferriols, Maria; (...); Gallego Ferrer, Gloria
Article. 10.3390/gels8100680. 2022
Mechanistic Understanding of Idiosyncratic Drug-Induced Hepatotoxicity Using Co-Cultures of Hepatocytes and Macrophages.
Villanueva-Badenas, Estela, Donato, M. Teresa, Tolosa, Laia
Article. 10.3390/antiox12071315. 2023
Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs
Gomez-Lechon, MJ, Tolosa, L, Donato, MT
Review. 10.1002/jat.3277. 2016
Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes
Quintas, G; (...); Castell, JV
Article. 10.1007/s00204-021-03114-z. 2021
Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved.
Martínez-Sena T; (...); Castell JV
Article. 10.1007/s00204-023-03474-8. 2023
Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen.
Rodríguez-Agudo R; (...); Martínez-Chantar ML
Article. 10.3390/antiox11050897. 2022
Mimicking cell-matrix crosstalk: bioinspired gelatin hydrogels functionalized with monomeric fibronectin as a liver in vitro model
Sanchez Gonzalez, Estela; (...); Gallego Ferrer, Gloria
Meeting Abstract. 2023
Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients
Thiel, C; (...); Kuepfer, L
Article. 10.1007/s00204-016-1723-x. 2017
Modeling a Novel Variant of Glycogenosis IXa Using a Clonal Inducible Reprogramming System to Generate "Diseased" Hepatocytes for Accurate Diagnosis.
Garcia-Llorens, Guillem; (...); Bort, Roque
Article. 10.3390/jpm12071111. 2022
Modelos Celulares hepáticos avanzados para el estudio preclíico del metabolismo y la hepatotoxicdad de fármacos.
MARÍA JOSÉ GÓMEZ-LECHÓN MOLINER
Article. 2017
Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid in human hepatocytes
Petrov, P. D.; (...); Jover, R.
Meeting Abstract. 2021
Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways.
Article. 10.1016/j.fct.2021.112664. 2021
Monitoring of system conditioning after blank injections in untargeted UPLC-MS metabolomic analysis.
Martínez-Sena T; (...); Kuligowski J
Article. 10.1038/s41598-019-46371-w. 2019
New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease
Lopez-Riera, M; (...); Jover, R
Article. 10.3389/fpahr.2017.00003. 2017
Newserum miRNA biomarkers to predict liver steatosis by valproic acid in paediatric epileptic patients
Jover, R.; (...); Castell, J. V.
Meeting Abstract. 10.1016/j.toxlet.2022.07.200. 2022
Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers
Lopez-Riera, M; (...); Jover, R
Article. 10.1038/s41598-018-28854-4. 2018
Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance
Clara-Trujillo S; (...); Gómez Ribelles JL
Article. 10.1016/j.bioadv.2022.212749. 2022
Outcomes of elective liver surgery worldwide: a global, prospective, multicenter, cross-sectional study
Malago, Massimo; (...); Andreoli, Gustavo
Article. 10.1097/JS9.0000000000000711. 2023
Oxidative-stress and long-term hepatotoxicity: comparative study in Upcyte human hepatocytes and hepaRG cells.
Article. 10.1007/s00204-022-03236-y. 2022
PIEZOELECTRIC 3D PLATFORM BASED ON HYDROGEL-POLY(VINYLIDENE FLUORIDE) MICROSPHERES FOR MESENCHYMAL STEM CELL OSTEOGENIC DIFFERENTIATION
Gallego-Ferrer, Gloria; (...); Luis Gomez-Ribelles, Jose
Meeting Abstract. 2022
Predicting drug-induced cholestasis: preclinical models
Petrov, PD; (...); Jover, R
Review. 10.1080/17425255.2018.1487399. 2018
Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations
Albrecht, W; (...); Hengstler, JG
Article. 10.1007/s00204-019-02492-9. 2019
Primary human hepatocytes-laden scaffolds for the treatment of acute liver failure.
Rodriguez-Fernandez J; (...); Tolosa L
Article. 10.1016/j.bioadv.2023.213576. 2023
Progress and challenges of mid-infrared spectroscopy for liver characterization focusing on steatosis, fibrosis and cancer
Ten-Domenech, Isabel; (...); Quintas, Guillermo
Review. 10.1080/05704928.2023.2215858. 2024
Protectiveness of NAM-based hazard assessment - which testing scope is required?
Zobl, Walter; (...); Escher, Sylvia E.
Article. 10.14573/altex.2309081. 2023
Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat
Quintas, Guillermo; (...); Jover, Ramiro
Article. 10.3390/ijms23169298. 2022
Regenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human induced pluripotent stem cells-derived hepatic stem cells.
Fourrier A; (...); Nguyen TH
Article. 10.1111/xen.12544. 2020
Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes.
Gu, XL; (...); Stoeber, R
Article. 10.1007/s00204-018-2302-0. 2018
Safer chemicals using less animals: kick-off of the European ONTOX project
Vinken, M; (...); Piersma, AH
Review. 10.1016/j.tox.2021.152846. 2021
Silencing of hepatic fate-conversion factors induce tumorigenesis in reprogrammed hepatic progenitor-like cells
Serrano F; (...); Bort R
Article. 10.1186/s13287-016-0349-5. 2016
Stem-cell derived hepatocyte-like cells for the assessment of drug-induced liver injury
Review. 10.1016/j.diff.2019.02.004. 2019
The assessment of the potential hepatotoxicity of new drugs by in vitro metabolomics.
Quintas, Guillermo, Castell, Jose V., Moreno-Torres, Marta
Article. 10.3389/fphar.2023.1155271. 2023
The in vitro assessment of the toxicity of volatile, oxidisable, redox-cycling compounds: phenols as an example
Tolosa, L; (...); Castell, JV
Article. 10.1007/s00204-021-03036-w. 2021
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment.
Moreno-Torres, Marta, Quintas, Guillermo, Castell, V, Jose
Article. 10.3390/metabo12060564. 2022
The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation.
Juárez-Fernández M; (...); Sánchez-Campos S
Article. 10.3390/antiox10122001. 2021
The Vitamin D Receptor Regulates Glycerolipid and Phospholipid Metabolism in Human Hepatocytes
Martinez-Sena, T; (...); Jover, R
Article. 10.3390/biom10030493. 2020
Toward Rapid Screening of Liver Grafts at the Operating Room Using Mid-infrared Spectroscopy.
Pérez-Guaita D; (...); Castell JV
Article. 10.1021/acs.analchem.0c02735. 2020
Uncovering the toxicity mechanisms of a series of carboxylic acids in liver cells through computational and experimental approaches.
Ortega-Vallbona, Rita; (...); Serrano-Candelas, Eva
Article. 10.1016/j.tox.2024.153764. 2024
Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing
Gomez-Lechon, MJ, Tolosa, L, Donato, MT
Review. 10.1080/17425255.2017.1238459. 2017
Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies
Donato, MT, Gomez-Lechon, MJ, Tolosa, L
Review. 10.1080/17460441.2017.1271784. 2017
Using Metabolomics to Uncover Ontogeny of Drug-Induced Hepatotoxicity and Underlying AOP Mechanisms
Martinez-Sena, T.; (...); Castell Ripoll, J. V.
Meeting Abstract. 2023
Which scope of NAM testing is sufficient for hazard characterisation? - An investigation based on transcriptomics data
Zobl, W.; (...); Escher, S. E.
Meeting Abstract. 10.1016/j.toxlet.2022.07.675. 2022
Caracterización Funcional De Hepatocitos Neonatales Criopreservados Para Su Uso En Terapia Celular Hepática
Autor/es: Rita Ortega Vallbona
Proyecto Fin de Carrera
Director/es: LAIA TOLOSA PARDO